EDSA Jumps 34% on Kyorin Deal: $12 Million Upfront, Bigger Tests Ahead
EDSA's 34% snapshot rally follows a Kyorin licensing deal. Examine the $12 million upfront payment, conditional milestones, clinical evidence and chart risks.
Read the story
EDSA's 34% snapshot rally follows a Kyorin licensing deal. Examine the $12 million upfront payment, conditional milestones, clinical evidence and chart risks.
Read the story